What does CUSIP 74366E102 represent in this 13F holders report?

CUSIP 74366E102 is the security identifier for PTGX - Protagonist Therapeutics, Inc - Common Stock used to aggregate holder disclosures.

How many institutions held PTGX - Protagonist Therapeutics, Inc - Common Stock in Q1 2021?

124 institutional investors reported PTGX - Protagonist Therapeutics, Inc - Common Stock for Q1 2021. Use the holders table for investor-level position and value details.

Protagonist Therapeutics, Inc - Common Stock (PTGX)

CUSIP: 74366E102

Q1 2021 13F Holders as of 31 Mar 2021

Type / Class: Equity / Common Stock
Shares outstanding: 62,457,444
Total 13F shares: 44,189,630
Share change: +891,610
Total reported value: $1,144,564,352
Put/Call ratio: 159%
Price per share: $25.90
Number of holders: 124
Value change: +$27,791,318
Number of buys: 63
Number of sells: 63

Quarterly Holders Quick Answers

What is CUSIP 74366E102?
CUSIP 74366E102 identifies PTGX - Protagonist Therapeutics, Inc - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Related Filing Research

Latest 13F filings for newly reported positions.
Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
Latest 10-Q/10-K reports for financial context tied to this issuer.
Recent insider transactions for executive and insider activity.
SEC investors directory and top value investors for manager drilldown.
Back to full security ownership history.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q2 2021
Previous quarter: Q4 2020

Recent filing periods for CUSIP 74366E102:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of PTGX - Protagonist Therapeutics, Inc - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
FMR LLC	13F	Company	10%	6,452,764	$130,087,000	—	31 Dec 2020	13F
BVF INC/IL	13F	Company	6.8%	4,273,588	$86,156,000	—	31 Dec 2020	13F
RTW INVESTMENTS, LP	13F	Company	5.8%	3,650,069	$73,585,000	—	31 Dec 2020	13F
Consonance Capital Management LP	13F	Company	4.4%	2,729,709	$55,031,000	—	31 Dec 2020	13F
BlackRock Finance, Inc.	13F	Company	4.1%	2,591,711	$52,248,000	—	31 Dec 2020	13F
Johnson & Johnson Innovation - JJDC, Inc.	13F	Company	3.9%	2,449,183	$49,376,000	—	31 Dec 2020	13F
FARALLON CAPITAL MANAGEMENT LLC	13F	Company	3.9%	2,425,000	$48,888,000	—	31 Dec 2020	13F
VANGUARD GROUP INC	13F	Company	3.2%	2,017,637	$40,675,000	—	31 Dec 2020	13F
STATE STREET CORP	13F	Company	2.4%	1,484,316	$29,924,000	—	31 Dec 2020	13F
BAKER BROS. ADVISORS LP	13F	Company	2.3%	1,436,192	$28,954,000	—	31 Dec 2020	13F
DEERFIELD MANAGEMENT COMPANY, L.P.	13F	Company	2.2%	1,379,971	$27,820,000	—	31 Dec 2020	13F
ADAGE CAPITAL PARTNERS GP, L.L.C.	13F	Company	1.8%	1,150,045	$23,185,000	—	31 Dec 2020	13F
Novo Holdings A/S	13F	Company	1.4%	867,724	$17,493,000	—	31 Dec 2020	13F
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	1.4%	845,395	$17,043,000	—	31 Dec 2020	13F
JPMORGAN CHASE & CO	13F	Company	1.1%	703,007	$14,172,000	—	31 Dec 2020	13F
DIMENSIONAL FUND ADVISORS LP	13F	Company	1%	649,540	$13,095,000	—	31 Dec 2020	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.88%	551,787	$11,124,000	—	31 Dec 2020	13F
Point72 Asset Management, L.P.	13F	Company	0.88%	550,000	$11,088,000	—	31 Dec 2020	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.81%	508,301	$10,247,000	—	31 Dec 2020	13F
NORTHERN TRUST CORP	13F	Company	0.65%	403,717	$8,139,000	—	31 Dec 2020	13F
TWO SIGMA ADVISERS, LP	13F	Company	0.59%	367,275	$7,404,000	—	31 Dec 2020	13F
Opaleye Management Inc.	13F	Company	0.42%	260,000	$7,020,000	—	31 Dec 2020	13F
Commodore Capital LP	13F	Company	0.56%	347,500	$7,006,000	—	31 Dec 2020	13F
CITADEL ADVISORS LLC	13F	Company	0.55%	340,822	$6,871,000	—	31 Dec 2020	13F
D. E. Shaw & Co., Inc.	13F	Company	0.54%	336,856	$6,791,000	—	31 Dec 2020	13F
Tri Locum Partners LP	13F	Company	0.42%	259,283	$5,227,000	—	31 Dec 2020	13F
PANAGORA ASSET MANAGEMENT INC	13F	Company	0.38%	236,682	$4,772,000	—	31 Dec 2020	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.36%	225,220	$4,541,000	—	31 Dec 2020	13F
PERCEPTIVE ADVISORS LLC	13F	Company	0.33%	203,591	$4,104,000	—	31 Dec 2020	13F
Altium Capital Management LLC	13F	Company	0.3%	185,854	$3,747,000	—	31 Dec 2020	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.25%	156,366	$3,152,000	—	31 Dec 2020	13F
INTERNATIONAL BIOTECHNOLOGY TRUST PLC	13F	Company	0.24%	152,000	$3,064,000	—	31 Dec 2020	13F
Twin Lakes Capital Management, LLC	13F	Company	0.23%	142,483	$2,872,000	—	31 Dec 2020	13F
BANK OF MONTREAL /CAN/	13F	Company	0.21%	133,574	$2,755,000	—	31 Dec 2020	13F
Artal Group S.A.	13F	Company	0.21%	133,000	$2,681,000	—	31 Dec 2020	13F
Laurion Capital Management LP	13F	Company	0.21%	130,158	$2,624,000	—	31 Dec 2020	13F
Bank of New York Mellon Corp	13F	Company	0.21%	129,304	$2,607,000	—	31 Dec 2020	13F
MARSHALL WACE, LLP	13F	Company	0.19%	116,794	$2,354,000	—	31 Dec 2020	13F
Atom Investors LP	13F	Company	0.16%	99,819	$2,012,000	—	31 Dec 2020	13F
Maven Securities LTD	13F	Company	0.14%	90,000	$1,814,000	—	31 Dec 2020	13F
Swiss National Bank	13F	Company	0.13%	82,700	$1,667,000	—	31 Dec 2020	13F
CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM	13F	Company	0.12%	75,373	$1,520,000	—	31 Dec 2020	13F
Gyon Technologies Capital Management, LP	13F	Company	0.12%	74,652	$1,505,000	—	31 Dec 2020	13F
Allianz Asset Management GmbH	13F	Company	0.12%	74,260	$1,498,000	—	31 Dec 2020	13F
WELLS FARGO & COMPANY/MN	13F	Company	0.12%	73,531	$1,483,000	—	31 Dec 2020	13F
Monashee Investment Management LLC	13F	Company	0.11%	70,000	$1,411,000	—	31 Dec 2020	13F
AMERIPRISE FINANCIAL INC	13F	Company	0.11%	66,855	$1,348,000	—	31 Dec 2020	13F
UBS Group AG	13F	Company	0.1%	64,933	$1,309,000	—	31 Dec 2020	13F
Global IMC LLC	13F	Company	0.1%	62,047	$1,251,000	—	31 Dec 2020	13F
Marshall Wace North America L.P.	13F	Company	0.1%	61,048	$1,230,000	—	31 Dec 2020	13F

Institutional Holders of Protagonist Therapeutics, Inc - Common Stock (PTGX) as of Q1 2021

As of 31 Mar 2021, Protagonist Therapeutics, Inc - Common Stock (PTGX) was held by 124 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 44,189,630 shares. The largest 10 holders included FMR LLC, BVF INC/IL, RTW INVESTMENTS, LP, BlackRock Inc., Consonance Capital Management LP, Johnson & Johnson Innovation - JJDC, Inc., Farallon Capital Management, L.L.C., VANGUARD GROUP INC, STATE STREET CORP, and BAKER BROS. ADVISORS LP. This page lists 124 institutional shareholders reporting positions in this security for the Q1 2021 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q1 2021 vs Q4 2020 Across Filers

Q4 2020 holders

124

Q1 2021 holders

124

Holder diff

Investor	Q4 2020 Shares	Q1 2021 Shares	Share Diff	Share Chg %	Q4 2020 Value $	Q1 2021 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.